Visit Twellow.com

Guidant Recalls Defibrillators That are Implanted in 50,000 People

Today Guidant Corp. announced that it is voluntarily recalling cardiac defibrillators, which about 50,000 people around the world have implanted in them.

The defibrillators have flaws that can lead to their malfunction, which can lead to the death of the person who has it implanted inside of them. At least two people with the defibrillators have died so far.

Guidant, which is based in Indianapolis, said that it is advising doctors about the safety of three models of defibrillators. There have been 45 cases in which the devices have failed.

The devices in question include :

  • VENTAK PRIZM 2 DR (Model 1861) ICDs manufactured on or before April 16, 2002.
  • CONTAK RENEWAL (Model H135) and CONTAK RENEWAL 2 (Model H155) CRT-Ds manufactured on or before August 26, 2004.
  • VENTAK PRIZM AVT, VITALITY AVT, RENEWAL 3 AVT and RENEWAL 4 AVT ICDs (All series numbers).
  • "Patient safety is paramount and our highest priority," stated Guidant President and CEO Ronald W. Dollens. "As a leading manufacturer of lifesaving technology, Guidant takes seriously its responsibility to create the most reliable products and services, enhance patient outcomes and limit adverse events to patients."

    "The purpose of the company's recent communications is to share information with physicians and patients about problems in a small subset of Guidant devices," continued Dollens. "We will work with physicians as they decide how best to treat their patients."

    Dollens added, "Guidant is committed to establishing industry guidelines and processes to determine when, how and under what circumstances adverse events should be communicated to doctors and patients. Guidant hopes to work with FDA, other regulatory agencies and physicians to convene a panel to assist the medical device industry in establishing clear guidelines."

    MarketWatch reports that Guidant shares fell 92 cents, or 1.3%, to $72.74 in recent trading. Guidant is being acquired by Johnson & Johnson, which was up18 cents to $66.48 in recent action.

    Chris is a staff writer for WebProNews. Visit WebProNews for the latest ebusiness news.

    Digg This! StumbleUpon This!
    AddThis Social Bookmark Widget

    News Tags: Recalls
    About the author:
    Chris Crum is a staff writer for WebProNews and iEntry Network.

    Comments

    Post new comment

    The content of this field is kept private and will not be shown publicly.
    CAPTCHA
    This question is for testing whether you are a human visitor and to prevent automated spam submissions.
    3 + 14 =
    Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.